About Us
About Noxopharm
CEO's Message
Management Team
Board of Directors
Scientific Advisors
Our Network
Pharmorage
ESG Commitment
Technology
Technology Platforms
Chroma™
Sofra™
mRNA Vaccines
Autoimmune Disease
Clinical Trials
Publications
Investor Centre
Share Price
Presentations & Interviews
Annual Reports
Financial Reports
ASX Announcements
Corporate Governance
Investor Fact Sheet
Share Registry Information
Contact Us
Contact Us
Partnering
Working at Noxopharm
ASX Announcements Email Alerts
Investor Centre
Investor Centre
>
ASX Announcements
Share Price
Presentations & Interviews
Annual Reports
Financial Reports
ASX Announcements
Corporate Governance
Investor Fact Sheet
Share Registry Information
ASX Announcements
Filter by Year:
2024
2023
2022
2021
2020
2019
2018
2017
Older
30 Apr 2021
Appendix 2A
30 Apr 2021
Change of Director's Interest Notice - BP
30 Apr 2021
Lapsing of Unlisted Options
30 Apr 2021
Publications Positive Review of Veyonda in Chemotherapy
29 Apr 2021
Notice of General Meeting/Proxy Form
27 Apr 2021
March Quarterly Activities Report and Appendix 4C
22 Apr 2021
Veyonda Showing Potential to Prevent Cytokine Storm
22 Apr 2021
Pause in Trading
12 Apr 2021
Cleansing Notice
12 Apr 2021
Appendix 2A
Previous
1
2
3
4
5
6
7
8
9
10
11
Next
